Comparative, controlled trial of treatment of minor uterine cavity abnormalities diagnosed by office hysteroscopy screening in women indicated for IVF.

Comparative, controlled trial of treatment of minor uterine cavity abnormalities diagnosed by office hysteroscopy screening in women indicated for IVF. - Treatment Efficacy of uterine Abnormalities (TEA) trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30448

Enrollment

200

Registered

2007-02-19

Start date

2007-06-28

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine cavity abnormalities

Interventions

Office Hysteroscopy procedure Hysteroscopy will be performed under supervision of the same investigating team (FB and MK) on an outpatient basis under paracervical block using in total 10 ml Xylocai

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Normal Transvaginal Ultrasound - No prior hysteroscopy - Age

Exclusion criteria

Exclusion criteria: - Recurrent miscarriage - Prior hysteroscopic treatments - Endometriosis >= AFS Stage III - Meno-metrorrhagia (defined as any intermenstrual loss of blood) - Submucosal/Intracavitary Fibroids taking more than 50% of the cavity - Hydrosalpinx - FSH/ LH > 12 IU/L on day 3 - Polyps taking more than 50 % of the cavity

Design outcomes

Primary

Measure	Time frame
The main study parameters are: Uterine cavity condition 1. Normal cavity (including uterus arcuatus), or 2. Predefined Cavitary Abnormality: - Partial septum (	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)